HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02696 HENLIUS

Market Closed 06-12 16:08:21

62.600

+5.700

+10.02%

High63.850	Low56.750	Vol1.40M
Open57.450	D1 Closing56.900	Amplitude12.48%
Mkt Cap34.12B	Tradable Cap21.78B	Total Shares545.00M
T/O85.71M	T/O Rate0.40%	Tradable Shares348.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"HENLIUS","latestPrice":62.6,"timestamp":1781251701006,"preClose":56.9,"halted":0,"volume":1400349,"delay":0,"changeRate":0.10017574692442888,"floatShares":348000000,"shares":545000000,"eps":1.7489518665203931,"marketStatus":"Market Closed","change":5.7,"latestTime":"06-12 16:08:21","open":57.45,"high":63.85,"low":56.75,"amount":85709538,"amplitude":0.12478,"askPrice":62.6,"askSize":300,"bidPrice":62.5,"bidSize":4400,"shortable":3,"etf":0,"ttmEps":1.7493944285546368,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":56.9,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":1.8409396024983395,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2643217858","title":"Shanghai Henlius Biotech (SEHK:2696) Stock Valuation After Pioneering Gastric Cancer Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2643217858","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643217858?lang=en_us&edition=fundamental","pubTime":"2026-06-13 23:18","pubTimestamp":1781363936,"startTime":"0","endTime":"0","summary":"Regulatory catalyst for Shanghai Henlius Biotech stock\nShanghai Henlius Biotech (SEHK:2696) is in focus after China’s National Medical Products Administration approved a new indication for its anti PD 1 therapy HANSIZHUANG in resectable gastric cancer.\nThe approval is built on positive phase 3 data showing better event free survival and safety versus standard chemotherapy. It also marks the first immune monotherapy regimen to replace adjuvant chemotherapy for gastric cancer in the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-stock-valuation-after-pion","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-stock-valuation-after-pion","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","HK0000306701.USD","BK4585","DCF","HK0000165453.HKD","HK0000320264.USD","02696","HK0000320223.HKD","XBI","HK0000306685.HKD","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115461891","title":"HENLIUS Shares Surge on Global First for its Key Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1115461891","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115461891?lang=en_us&edition=fundamental","pubTime":"2026-06-12 13:58","pubTimestamp":1781243906,"startTime":"0","endTime":"0","summary":"HENLIUS (SEHK: 02696) shares rose over 8% in trading today.At the time of writing, the stock was up 8.52% to HK$61.75, with a trading turnover exceeding HK$42.21 million.The significant move follows...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","HK0000320264.USD","BK1161","02696","HK0000165453.HKD","BK4588","HK0000320223.HKD","VXUS","BK4585","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144732181","title":"Henlius issues 1.71 million new H shares for 2025 RSU scheme, expanding share base by 0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144732181","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144732181?lang=en_us&edition=fundamental","pubTime":"2026-06-11 18:03","pubTimestamp":1781172193,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (Henlius) disclosed on 11 June 2026 that it has allotted and issued 1.71 million new H shares to the trustee of its 2025 H Share Restricted Share Unit (RSU) Scheme. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168029435","title":"HENLIUS Issues Approximately 1.71 Million Shares for 2025 H-Share Restricted Share Unit Plan Settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=1168029435","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168029435?lang=en_us&edition=fundamental","pubTime":"2026-06-11 17:32","pubTimestamp":1781170361,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) has announced the issuance of new shares.The company allotted and issued a total of approximately 1.71 million new shares on June 11, 2026, to the trustee of its 2025 H-Share...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","HK0000306685.HKD","HK0000165453.HKD","02696","BK1161","HK0000320223.HKD","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642414405","title":"Fosun’s Henlius wins China NMPA approval for serplulimab in perioperative gastric cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642414405","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642414405?lang=en_us&edition=fundamental","pubTime":"2026-06-10 11:28","pubTimestamp":1781062138,"startTime":"0","endTime":"0","summary":"Fosun unit Henlius secured China NMPA clearance for serplulimab in perioperative PD-L1-positive resectable gastric cancer under priority review.Label covers neoadjuvant use with oxaliplatin and S-1, followed by adjuvant serplulimab monotherapy, replacing postoperative chemotherapy.Phase 3 ASTRUM-006 cut event risk 33% in CPS ≥5 patients, with 21.6% pathological complete response and 96.7% R0 resection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL1p7yCn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","02696","HK0000306685.HKD","BK1230","00656","BK1161","HK0000320264.USD","HK0000306701.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642608814","title":"Henlius Biotech's Application for New Indication of Hansizhuang Approved in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2642608814","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642608814?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:31","pubTimestamp":1781008288,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech's (HKG:2696) new drug application for a new indication of Hansizhuang was approved by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","HK0000306685.HKD","HK0000320264.USD","HK0000165453.HKD","XBI","BK4585","BK4581","02696","HK0000306701.USD","HK0000320223.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190108749","title":"HENLIUS's H Drug Advances Global Strategy and Pipeline Depth: Reaches 50 Markets, Targets Next Challenging Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1190108749","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190108749?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:11","pubTimestamp":1781007077,"startTime":"0","endTime":"0","summary":"On June 9, 2026, the New Drug Application (NDA) for the anti-PD-1 monoclonal antibody H drug, Hansizhuang® (serplulimab, European brand name: Hetronifly®), developed by HENLIUS (02696), was...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","HK0000320264.USD","BK1161","02696","HK0000165453.HKD","HK0000320223.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165361021","title":"Henlius receives NMPA approval for Hansizhuang neo-/adjuvant gastric cancer regimen","url":"https://stock-news.laohu8.com/highlight/detail?id=1165361021","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165361021?lang=en_us&edition=fundamental","pubTime":"2026-06-09 18:23","pubTimestamp":1781000594,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (HENLIUS) announced that China’s National Medical Products Administration has cleared a new indication for Hansizhuang (serplulimab injection). The anti-PD-1 antibody,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164113398","title":"Henlius Receives NMPA Approval for New Gastric Cancer Indication of Serplulimab Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1164113398","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164113398?lang=en_us&edition=fundamental","pubTime":"2026-06-09 18:16","pubTimestamp":1781000208,"startTime":"0","endTime":"0","summary":"The National Medical Products Administration (NMPA) has recently approved the new drug application (NDA) for a new indication of HENLIUS' (02696) self-developed innovative anti-PD-1 monoclonal...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000320223.HKD","HK0000320264.USD","IPOS","HK0000306701.USD","HK0000306685.HKD","BK1161","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642109469","title":"Shanghai Henlius Biotech - Nmpa Approves Nda for Hansizhuang for Neo-/Adjuvant Treatment of Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642109469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642109469?lang=en_us&edition=fundamental","pubTime":"2026-06-09 18:10","pubTimestamp":1780999823,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nFWN42G15H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000320264.USD","HK0000165453.HKD","02696","HK0000306701.USD","HK0000320223.HKD","HK0000306685.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641449781","title":"Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation After China’s Broad HANBEIYOU Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2641449781","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641449781?lang=en_us&edition=fundamental","pubTime":"2026-06-05 22:19","pubTimestamp":1780669189,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved its pertuzumab biosimilar HANBEIYOU for all local reference indications, completing a China, US and EU approval set.\nSee our latest analysis for Shanghai Henlius Biotech.\nDespite the HANBEIYOU catalyst and a string of recent trial starts in oncology and immunology, Shanghai Henlius Biotech’s share price has been under pressure in the near term, with the 7 day and 30...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-after-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-after-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XBI","HK0000306701.USD","HK0000320264.USD","DCF","BK4585","HK0000165453.HKD","BK1161","HK0000306685.HKD","HK0000320223.HKD","BK4588","BK4581","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641480114","title":"Henlius Biotech Doses First Patient in US Tumor Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2641480114","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641480114?lang=en_us&edition=fundamental","pubTime":"2026-06-05 18:25","pubTimestamp":1780655135,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech  dosed the first patient in an international multi-center phase 1 study of a HLX17 in the United States, according to a Friday Hong Kong bourse filing.The trial is studying the drug in patients with multiple resected solid tumors.A phase 1 trial of the drug is simultaneously being conducted in Mainland China.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02696","BK4581","BK4588","BK4585","HK0000306701.USD","BK1161","HK0000165453.HKD","HK0000320264.USD","XBI","HK0000306685.HKD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129934396","title":"Henlius: First Patient Dosed in Global Phase 1 Trial of Pembrolizumab Biosimilar HLX17","url":"https://stock-news.laohu8.com/highlight/detail?id=1129934396","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129934396?lang=en_us&edition=fundamental","pubTime":"2026-06-05 16:49","pubTimestamp":1780649386,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (Henlius) announced the first patient dosing in an international, multi-center Phase 1 clinical study of HLX17, a biosimilar to pembrolizumab, in patients with multiple...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179396585","title":"Henlius Announces First US Patient Dosed in International Phase 1 Trial for Pembrolizumab Biosimilar HLX17 in Resected Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1179396585","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179396585?lang=en_us&edition=fundamental","pubTime":"2026-06-05 16:36","pubTimestamp":1780648618,"startTime":"0","endTime":"0","summary":"HENLIUS (ASX: 02696) has announced that the first patient in the United States has been dosed in its international multi-center Phase 1 clinical study for HLX17, the company's self-developed...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","HK0000306701.USD","HK0000320223.HKD","HK0000320264.USD","HK0000165453.HKD","02696","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144008268","title":"HENLIUS' Trastuzumab-Pertuzumab Combo Gains Global Foothold with Third Major Market Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1144008268","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144008268?lang=en_us&edition=fundamental","pubTime":"2026-06-05 15:31","pubTimestamp":1780644660,"startTime":"0","endTime":"0","summary":"China's breast cancer biosimilar market sees a significant new entrant. HENLIUS has announced that its Pertuzumab Injection, HANBEYOU®, has received marketing approval from China's National Medical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000306701.USD","BK1161","HK0000165453.HKD","HK0000320264.USD","HK0000306685.HKD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146228118","title":"CICC Reiterates Outperform Rating on Henlius with HK$102.91 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1146228118","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146228118?lang=en_us&edition=fundamental","pubTime":"2026-06-05 10:02","pubTimestamp":1780624960,"startTime":"0","endTime":"0","summary":"CICC has released a research report maintaining its current earnings forecasts for Henlius (02696). The stock currently trades at 27.2x/25.7x its estimated FY26/FY27 P/E. Based on the firm's view of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","HK0000320223.HKD","HK0000165453.HKD","BK1161","HK0000306685.HKD","02696","EWH","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147358861","title":"Henlius Reports Stable Share Capital for May 2026; Minor Lapses in Option and RSU Pools","url":"https://stock-news.laohu8.com/highlight/detail?id=1147358861","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147358861?lang=en_us&edition=fundamental","pubTime":"2026-06-03 17:05","pubTimestamp":1780477520,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. filed its May 2026 monthly return, confirming that the company’s share structure remained unchanged during the period. Total authorised and registered share capital...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640793714","title":"Fosun’s Henlius wins China NMPA approval for pertuzumab biosimilar HANBEIYOU","url":"https://stock-news.laohu8.com/highlight/detail?id=2640793714","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640793714?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:19","pubTimestamp":1780305592,"startTime":"0","endTime":"0","summary":"Fosun unit Henlius won China NMPA clearance for pertuzumab biosimilar HANBEIYOU for HER2-positive early-stage, adjuvant, neoadjuvant, metastatic breast cancer.The product now holds regulatory authorizations in China, the US, the EU; US label includes interchangeability with Roche’s Perjeta.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL1MCXlp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","HK0000165453.HKD","00656","02696","BK1230","HK0000306701.USD","BK1161","HK0000320264.USD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639988328","title":"Mabwell Bioscience proposes new board slate as four directors retire","url":"https://stock-news.laohu8.com/highlight/detail?id=2639988328","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639988328?lang=en_us&edition=fundamental","pubTime":"2026-05-31 19:55","pubTimestamp":1780228533,"startTime":"0","endTime":"0","summary":"Mabwell proposed a new board lineup at a June 18, 2026 EGM, setting up leadership continuity under chairman and general manager Liu Datao.Executive director slate includes Liu, founder Tang Chunshan, R&D president Wu Hai, CFO Hua Jun; Gui Xun to be chosen separately as employee director.Retirements planned for Hu Huiguo, Wu Yufeng, Xu Qing, Zhao Qian once new directors are elected; Hu stays as deputy general manager.Wu Hai previously held senior R&D roles at Amgen, Trellis Bioscience; served at Junshi as deputy general manager and director.Hua Jun previously worked in finance roles at GE, Johnson & Johnson, Roche, Hutchison MediPharma; later ran finance and procurement at Henlius.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabwell ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260531:nNDL2sRq5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","IE00BFTCPJ56.SGD","BK1161","BK4566","HK0000165453.HKD","IE00B4R5TH58.HKD","BK4581","BK4585","LU0320765992.SGD","LU0289739699.SGD","LU0889565916.HKD","HK0000320264.USD","SG9999001440.SGD","LU0868494617.USD","IE00BJT1NW94.SGD","BK4534","BK4139","LU2089984988.USD","LU1057294990.SGD","IE00B2B36J28.USD","AMGN","IE00BJJMRZ35.SGD","LU2468319806.SGD","HK0000320223.HKD","LU2242652126.USD","BK4599","HK0000306701.USD","LU2112291526.USD","688062","BK4533","LU0058720904.USD","BK4588","02696","IE0002141913.USD","LU2242646821.SGD","LU1023059063.AUD","HK0000306685.HKD","IE0009355771.USD","LU1571399168.USD","LU1983299246.USD","LU0109394709.USD","00656","BK1230","LU0122379950.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639621882","title":"Henlius Biotech Gets China Nod for Breast Cancer Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2639621882","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639621882?lang=en_us&edition=fundamental","pubTime":"2026-05-29 18:34","pubTimestamp":1780050878,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech  obtained approval for the new drug application for HANBEIYOU  from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approved indications are for the treatment of patients with various forms of breast cancer.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000165453.HKD","XBI","BK4585","HK0000306685.HKD","HK0000306701.USD","HK0000320223.HKD","BK4588","HK0000320264.USD","BK4581","BK1161","02696"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0399},{"period":"1month","weight":-0.0928},{"period":"3month","weight":-0.0615},{"period":"6month","weight":-0.034},{"period":"1year","weight":0.2934},{"period":"ytd","weight":0.0973}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.12138},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.033714},{"month":6,"riseRate":0.571429,"avgChangeRate":0.081457},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"HENLIUS","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HENLIUS,02696,HENLIUS股票,HENLIUS股票老虎,HENLIUS股票老虎国际,HENLIUS行情,HENLIUS股票行情,HENLIUS股价,HENLIUS股市,HENLIUS股票价格,HENLIUS股票交易,HENLIUS股票购买,HENLIUS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}